Ligand Pharmaceuticals Incorporated 13D and 13G filings for Seelos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-01-15 4:11 pm Unchanged |
2020-12-31 | 13G | Seelos Therapeutics, Inc. SEEL |
LIGAND PHARMACEUTICALS INC LGND |
579 4.100% |
0 (Unchanged) |
Filing |